Healthcare

PRODUCTS

  • iMednet EDC
    Streamline Electronic Data Capture With iMednet EDC

    At the core of our comprehensive eClinical platform, iMednet EDC is uniquely designed to help sponsors and CROs achieve their clinical research goals. Highly flexible, it enables you to build studies quickly, while easily adapting to complex protocols and mid-study changes with ease.

  • Germfree - compounding operations
    Panels For Compounding Operations And Critical Environments

    The healthcare industry demands durable, cleanable, and safe environments. Arcoplast offers a comprehensive solution for critical areas like operating rooms, cleanrooms, and compounding pharmacies.

  • Medicine-pills-tablets-GettyImages-545993684
    USP<1062> Tablet Compression Characterization

    Natoli Scientific takes pride in its comprehensive USP<1062> Tablet Compression Characterization services, tailored to address the complexities of tableting in pharmaceutical manufacturing. Staying true to the parameters outlined in the United States Pharmacopeia (USP) Chapter 1062, our approach meticulously evaluates tablet compression behaviors. By thoroughly characterizing the compression profile, we can pinpoint the optimal compression force required to form a cohesive tablet without applying undue stress that could lead to capping — the separation of tablet tops during or after the compression phase.

  • trailkit econsent
    eConsent For Clinical Trials

    Help your patients make informed decisions without burying them in paper

    With electronic informed consent (eConsent) software, your patients can access consent forms using any device they choose. And because it’s part of TrialKit’s unified platform, both your patients and your study team get a seamless experience.

  • GettyImages-849207658 Drug toxicity concept
    NDA Submissions 505(b)(1) Or 505(b)(2)

    There are clearly defined pathways for drug approval, and choosing the right regulatory pathway for your drug development program requires a thorough understanding of sections 505(b)(1) and 505(b)(2) of the Federal Food, Drug, and Cosmetics (FD&C) Act.

WHITE PAPERS AND CASE STUDIES

NEWS